Living with someone who has COVID-19 creates a uniquely high transmission risk, particularly for families unable to completely isolate infected members. This vulnerability has persisted throughout the pandemic without proven pharmaceutical interventions to protect exposed household members before symptoms develop.
Ensitrelvir, a 3C-like protease inhibitor already approved in Japan for COVID treatment, demonstrated significant protective effects when given to uninfected household contacts within 72 hours of the index patient's symptom onset. In this randomized controlled trial involving over 2,000 participants, the five-day oral regimen reduced COVID-19 development by approximately 45% compared to placebo. The treatment protocol required just six pills total: a higher dose on day one followed by smaller maintenance doses.
This represents the first clinically proven antiviral strategy for COVID postexposure prophylaxis in household settings, addressing a critical gap in pandemic response tools. The protease inhibitor mechanism differs from Paxlovid's approach, potentially offering alternatives for resistant variants or drug interactions. However, several factors limit immediate global applicability: the study population was predominantly Japanese, variant circulation differs across regions, and regulatory approval remains limited. The 72-hour window also requires rapid access to testing and prescription systems. While promising for high-risk households, questions remain about cost-effectiveness compared to improved ventilation, masking, and isolation protocols. The findings suggest antiviral prophylaxis could become standard care for vulnerable household members, though broader implementation will require additional safety data across diverse populations and healthcare systems.